# Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

> **NCT05630001** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** Iptacopan

## Key facts

- **NCT ID:** NCT05630001
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-24
- **Primary completion:** 2024-10-17
- **Final completion:** 2024-10-17
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630001, "Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05630001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*